Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)

Phase 3 Completed 40 enrolled Vance Thompson Vision ND

RandomizedParallel-groupTriple-blindTreatment

Summary

Evaluate the safety and effectiveness of OC-01 (varenicline) nasal spray for amelioration of signs and symptoms of dry eye disease in subjects following laser-assisted in situ keratomileusis (LASIK).

Timeline

Start: 2021-10-20
Primary completion: 2022-08-03
Completion: 2022-08-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Varenicline	Small molecule	0.6 mg/ml	Intranasal

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)

Summary

Timeline

Drugs

Indications